JY
MIRM icon

Jeff Yass’s Mirum Pharmaceuticals MIRM Stock Holding History

Jeff Yass’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.9M Sell
67,500
-29,700
-31% -$2.98M ﹤0.01% 3773
2026
Q1 		$8.98M Buy
97,200
+71,000
+271% +$6.68M ﹤0.01% 3284
2025
Q4 		$2.07M Sell
26,200
-12,400
-32% -$890K ﹤0.01% 5583
2025
Q3 		$2.83M Buy
38,600
+31,800
+468% +$2.02M ﹤0.01% 5086
2025
Q2 		$346K Buy
+6,800
New +$303K ﹤0.01% 10021
2024
Q4 		– Sell
-13,600
Closed -$530K – 12828
2024
Q3 		$530K Buy
+13,600
New +$543K ﹤0.01% 8316
2024
Q2 		– Sell
-10,400
Closed -$261K – 12788
2024
Q1 		$261K Buy
10,400
+3,300
+46% +$90.7K ﹤0.01% 10024
2023
Q4 		$210K Sell
7,100
-28,900
-80% -$875K ﹤0.01% 10582
2023
Q3 		$1.14M Buy
+36,000
New +$986K ﹤0.01% 6346
2022
Q2 		– Sell
-14,400
Closed -$317K – 13547
2022
Q1 		$317K Buy
14,400
+400
+3% +$8.16K ﹤0.01% 10142
2021
Q4 		$223K Sell
14,000
-10,000
-42% -$156K ﹤0.01% 11215
2021
Q3 		$478K Buy
+24,000
New +$390K ﹤0.01% 9504

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jeff Yass's MIRM Position: Q2 2026 in Review

Jeff Yass reduced its Mirum Pharmaceuticals (MIRM) stake by 67% in Q2 2026, selling an estimated $1.65M and leaving 7,924 shares worth $928K. The position accounts for ﹤0.01% of the portfolio, ranked #8384.

Jeff Yass first reported a position in MIRM in Q1 2021 and has held it in 22 quarters since. The position peaked at $2.67M in Q2 2025. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • Jeff Yass held 7,924 shares of Mirum Pharmaceuticals worth $928K as of Q2 2026.
  • Jeff Yass sold 16,393 Mirum Pharmaceuticals shares in Q2 2026, an estimated $1.65M.
  • Mirum Pharmaceuticals made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #8384 holding.
  • Jeff Yass first reported a position in Mirum Pharmaceuticals in Q1 2021 and has held it in 22 quarters since.
  • Jeff Yass's Mirum Pharmaceuticals position peaked at $2.67M in Q2 2025.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.